Evosep Jun 17 2025 Evosep, a global leader in robust, high-throughput proteomics technologies, has been selected as the proteomics platform provider for the P4ML - OMICAssist Study—the world's largest multi-omic precision medicine initiative, launched by P4ML alongside its strategic academic, health regulatory, and semi-state partners in the United Arab Emirates. Evosep headquarters in Odense, Denmark. Image Credit: Evosep Over the next five years, the study will screen more than two million